BIOMARIN PHARMACEUTICAL $64.01

down -0.49


17/5/2013 05:17 PM  |  NASDAQ : BMRN  |  Industries : Manufacturing / Pharmaceutical and Medicine Manufacturing
12 Mo. Price Change : 66% - BMRN has outperformed the S&P 500 by 41%

Get Trend Analysis Icon Get Trend Analysis

Partner Headlines

  1. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus

  2. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus

  3. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus

  4. UPDATE: Stifel Nicolaus Upgrades BioMarin Pharmaceutical on Catalysts

    Benzinga

  5. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus

  6. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus

  7. J.P. Morgan Reiterates Overweight Rating, $60 PT on BioMarin ...

    Benzinga

  8. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus

  9. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus

  10. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus

  11. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus

  12. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus

  13. UPDATE: Wedbush Reiterates BioMarin Pharmaceuticals at Neutral ...

    Benzinga

  14. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus

  15. BioMarin, Prestige Brands and Other Top Performing Health Care ...

    Benzinga

  16. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus

  17. Weekly Top Insider Sells? AAPL, GILD, BMRN, and PCLN

    GuruFocus

  18. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus

  19. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus

  20. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus

  21. Myriad Genetics Stock Hits High On Earnings Beat

    Investors Business Daily

  22. Highs & Lows: BioMarin Pharmaceutical, Best Buy, and Skullcandy

    By SchaeffersResearch

  23. BioMarin soars on drug data

    Investors Business Daily

  24. Mid-Afternoon Market Update: Markets Rally, Vringo Jumps

    Benzinga

  25. UPDATE: Canaccord Genuity Raises PT to $56 on BioMarin ...

    Benzinga

  26. Mid Morning Market Update: Markets Decline, Stifel Financial ...

    Benzinga

  27. Stocks Hitting 52-Week Highs

    Benzinga

  28. BioMarin Stock Soars On Positive Drug Data

    Investors Business Daily

  29. BioMarin Phase 3 Study of GALNS Meets Primary Endpoint

    Benzinga

  30. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus

  31. BioMarin Pharmaceutical Inc. Reports Operating Results (10-Q)

    GuruFocus

  32. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus

  33. UPDATE: Jefferies Raises PT to $46 on BioMarin Pharmaceutical ...

    Benzinga

  34. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus

  35. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus

  36. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus

  37. Health Care Sector Wrap

    FOXBusiness

  38. Benzinga's Top Downgrades

    Benzinga

  39. Biotechs In Motion As New Drug Pipeline Brims

    Investors Business Daily

  40. BioMarin Pharmaceutical Reports Inducement Grants Under NASDAQ ...

    Benzinga

  41. Dendreon, Pharmacyclics and Other Biotech Takeover Targets

    Benzinga

  42. BioMarin Pharmaceutical, Health Net Among Stocks Up on High Volume ...

    FOXBusiness

  43. Merck &, Questcor Pharmaceuticals, Other Stocks Hit 52-Week Highs ...

    FOXBusiness

  44. Amylin Pharmaceuticals, Constellation Brands Among Stocks Setting ...

    FOXBusiness

  45. Analyst Initiations: BMRN, FB, and MDVN

    By SchaeffersResearch

  46. Benzinga's Top Pre-Market Gainers

    Benzinga

  47. From Earlier: Wedbush Reiterates BioMarin Pharmaceuticals Neutral, ...

    Benzinga

  48. Benzinga's Morning Initiation Summary for June 1, 2012

    Benzinga

  49. BioMarin Pharmaceutical (BMRN) Loses 7.2% After Pricing Offering ...

    At Market Intelligence Center

  50. BioMarin Announces Pricing of Public Offering of Common Stock; ...

    Benzinga

  51. UPDATE: Citi Raises BioMarin Pharmaceuticals' PT

    Benzinga

  52. BioMarin Pharmaceutical (BMRN) Loses 1.3% as Volatility Continues

    At Market Intelligence Center

  53. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus

  54. 5 Resilient Biotech Stocks to Buy for 2012

    at GuruFocus

  55. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    at GuruFocus

  56. BioMarin Pharmaceutical Inc. (BMRN) SVP, CFO Jeffrey H Cooper ...

    at GuruFocus

  57. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    at GuruFocus

  58. Upgrades & Downgrades: YHOO, BMRN, HGSI, DNDN, and TSLA

    By SchaeffersResearch

  59. Just What The Doctor Ordered: 4 ETFs For Biotech M&A

    at Benzinga

  60. BioMarin Pharmaceutical Inc. (BMRN) SVP, CFO Jeffrey H Cooper ...

    at GuruFocus

  61. Stocks at New Highs: BioMarin Pharmaceutical and Seattle Genetics

    By SchaeffersResearch

  62. Call Volume Spikes on BioMarin Pharmaceutical

    By SchaeffersResearch
People viewing BMRN also viewed: , , , , , ,
Marketplace
Trading Center